Kornimate/medical-research-clean huggingface dataset:
turkish adaptation, validity and reliability of community integration questionnaire-revised (ciq-r)

Conditions: Stroke; Community Integration

Summary: the aim of this study is to adapt the community integration questionnaire-revised (ciq-r) scale to turkish society and to make its validity and reliability in turkish. the ciq-r scale developed by callaway et al assesses home integration, social integration, productivity, and electronic social networking in neurological diseases. it has 18 questions. this study will be conducted with stroke patients. the patients will be sought to answer questionnaires during regular rehabilitation sessions. 130 participants will be included in the study. in order to evaluate the validity of the ciq-r, the mini mental state examination (mmse), which can evaluates general cognitive functioning and has been validated in turkish, will be used. scales will be repeated after 15 days to assess test-retest reliability.

the reliability and validity of the scale will begin with language equivalence and cultural adaptation. the scale will be translated from english to turkish by two people who are fluent in turkish and english. a single turkish translation will be obtained from these two turkish translations with a common opinion. the scale, which has been translated into turkish, will be translated into english by two other people who are fluent in turkish and english. the scale translated into english will be compared with the original. if the developer of the scale, callaway and willer approves the translation of the scale, participants will be recruited for the study. in the pre-trial phase, a reassessment will be conducted with 15 participants to test the intelligibility of the scale. based on the results of the pre-test phase, the final version of ciq-r will be able to be modified. the data of ciq-r are collecting through face-to-face when the patients came to the rehabilitation center. 145 participants will be included in the study. in order to evaluate the validity of the ciq-r, the mini mental state examination (mmse), which can evaluates general cognitive functioning and has been validated in turkish, will be used. scales will be repeated after 15 days to assess test-retest reliability.

Eligibility criteria:
inclusion criteria: patients with * duration of hemiplegia ≤ 3 year * able to speak and read turkish * those with a mini mental state examination score of 24 and above exclusion criteria: patients with * communication or cognitive problems, * aphasia and speech disorders * unstable medical conditions

Keywords: stroke social networking social participation community integration
pk and pd of drugs for nontuberculous mycobacterial diseases in dutch patients

Conditions: Nontuberculous Mycobacterial Diseases

Summary: a prospective observational study in which pharmacokinetic and pharmacodynamic parameters are evaluated in a cohort of patients with ntm diseases.

ntm are widely distributed in the environment and can especially be found in soil and water sources. these bacteria a very similar to tuberculosis bacteria. we are not that long aware that these bacteria can cause illness. especially in patients with a chronic lung disease are sensitive to these bacteria and are susceptible to develop an infection. a lot of ambiguity consists about the best treatment of these infections. up till now mainly the normal treatment for tuberculosis is used, however, the time period during which these medicines should be used and what dose should be used is mainly unknown. to investigate whether the dose used at this moment is right a pharmacokinetic curve will be taken at steady-state.

Eligibility criteria:
inclusion criteria: * currently treated for ntm infection or recently diagnosed with ntm infection starting treatment at university centre for chronic diseases dekkerswald (groesbeek), centre for revalidation beatrixoord (haren), or other outpatient clinics in the netherlands. * diagnosis and treatment according to american thoracic society (ats) criteria for ntm infections. patients with pulmonary ntm infections (possible with extrapulmonary localizations as well) are eligible * treated with at least rifampicin and ethambutol and optionally with isoniazid, clarithromycin or azithromycin on a daily basis * age at least 18 years * patient has been using drugs for at least two weeks when steady state concentrations of the used drugs are expected * informed consent has been signed exclusion criteria: * the medical state of the patients does not allow inclusion according to the physician in attendance. * the patients' clinical parameters urge immediate cessation of drugs. * the patient is pregnant. * significant hepatic or renal dysfunction based on chemistry parameters (grade 1 according to an international adverse event grading system, see http:/ctep.cancer.gov) or symptomatic liver dysfunction (nausea and vomiting). * patients with cystic fibrosis, since these show deviating pharmacokinetics for many drugs. * patients with hiv infection, since these may show deviating pharmacokinetics for the drugs used in ntm disease.

Keywords: nontuberculous mycobacterial diseases pharmacokinetics pharmacodynamics
office-based superior laryngeal nerve block for treatment of neurogenic cough

Conditions: Cough

Summary: the purpose of this study is to evaluate if office-based injection of a local anesthetic/steroid combination at the area of one superior laryngeal nerve can decrease cough frequency and alleviate symptoms of chronic cough in patients with neurogenic cough.

neurogenic cough is a chronic cough without a clear cause. it is thought to be related to irritation of a nerve that goes to the larynx (voice box). this can happen after a viral upper respiratory infection. current treatment uses therapy or medications taken by mouth. those medications can be sedating and not well tolerated. an alternative approach would be to perform an injection "nerve block", which is commonly done for other nerve disorders such as around the spine. this may help people with neurogenic cough also. we studied this recently in a small group of patients and found that patients had improvement in their cough symptoms (simpson 2018). it would be helpful to study this in a larger group of patients using more methods of evaluating cough symptom severity.

Eligibility criteria:
inclusion criteria: * age 18 years or older * ability of patients to speak and understand english * ability for patients to consent for themselves * cough for 8 weeks or greater, with suspected sensory neuropathic etiology of the cough. inclusion based on history of preceding upper respiratory infection or other symptoms suggestive of irritable larynx such as cough in response to temperature changes, odors, scents/perfumes, tickle, irritation in the throat/paralaryngeal region, or talking. * persistent cough despite treatment of all the major contributors of cough (items listed below would be done as part of a standard clinical workup for chronic cough and are not done specific to this study): * reflux disease treatment with one of the following: failure of two months of ppis or negative ph study * asthma: lack of response to at least one month of steroid inhaler/bronchodilator or normal pfts/negative methacholine challenge + negative cxr/ct * upper airway cough syndrome/allergic disease: lack of response to at least one month of antihistamines/decongestants/nasal steroids or negative allergy testing (skin or serum) or lack of response to at least one year of immunotherapy/allergy shots exclusion criteria: * age less than 18 years * patients unable or unwilling to provide informed consent * known etiology to cough other than sensory neuropathy (e.g., reflux disease, asthma, allergic rhinitis, chronic obstructive pulmonary disease) * addition of new neuromodulators at the time of the injection. patients who were already being treated with neuromodulators for their cough (e.g., gabapentin, amitriptyline) will not be excluded provided their dose remains constant. * nissen fundoplication within the last year * smoking history within last 5 years * allergy to bupivacaine or kenalog-40

Keywords: chronic cough
efficacy, safety, and treatment patterns of transcatheter arterial chemoembolization (tace) combined with atezolizumab and bevacizumab in unresectable hepatocellular carcinoma: a multicenter, retrospective, observational real-world study

Conditions: HCC

Summary: this study will evaluate the efficacy and safety of tace combined with atezolizumab + bevacizumab in the treatment of unresectable hepatocellular carcinoma, and the treatment patterns of the combination regimen

this study is a multi-center, retrospective and observational real-world study to explore the efficacy, safety and treatment pattern of tace combined with atezolizumab + bevacizumab in unresectable hepatocellular carcinoma. the target population for the planned retrospective analysis of this project is patients who have been diagnosed with unresectable hcc according to the guidelines for diagnosis and treatment of primary liver cancer in china (2019 edition) and treated with tace combined with atezolizumab + bevacizumab.

Eligibility criteria:
inclusion criteria: 1. all patients were diagnosed with unresectable hepatocellular carcinoma according to the guidelines for diagnosis and treatment of primary liver cancer in china (2019 edition); 2. patients ≥ 18 years old, male or female; 3. child-pugh class a and b liver function; 4. ecog-ps score of 0 \~ 2 points; 5. received tace in combination with atezolizumab + bevacizumab for at least one interval of no more than eight weeks. exclusion criteria: 1. other primary malignancies; 2. incomplete data, such as no baseline image that can be assessed according to recist 1.1 or mrecist, and survival outcome.
is tunneling effective in preventing failure of epidural analgesia? a randomized trial

Conditions: Epidural Catheter; Post Operative Pain

Summary: this is a prospective randomized single blinded study in patients planned to undergo general anesthesia and epidural catheter insertion for pain control after abdominal, thoracic and orthopedic surgery. patients meeting participation criteria will be selected and enrolled sequentially. the study recruitment will be carried out over one year with follow-up for each patient until either the catheter is dislodged or once decided that the patient is to be discontinued from the epidural pain control.

study population and sample size the study aims to enroll 200 adult patients planned to undergo general anesthesia and epidural catheter insertion. the study sample will be selected to fulfill the selection criteria. patients will be selected if they meet the following participation criteria: planned procedures and assessments follow -up on dislodgments, adverse events, pain and pain relief assessment, standard practice study site all study conduction from start to end including procedures and assessments, data acquisition and analysis and final study conclusion report and any publications will be at king hussein cancer center (khcc). ethical considerations the study will be submitted to the khcc irb for review. the study will not start before irb approval is obtained. all patients who provide consent to participation in the study will be randomized and enrolled. statistical plan descriptive statistics will be used to present the two groups baseline characteristics. comparison between groups will be carried out using chi-square test or t-test or wilcox on rank test as appropriate. comparison between groups while adjusting for other variables will be carried out using logistic regression. odds ratios along with their 95% confidence intervals will be calculated.

Eligibility criteria:
inclusion criteria: * patient is an adult, between 18-80 years old with normal mentation. * patient has consented to general anesthesia and epidural catheter insertion for pain control after abdominal, thoracic and orthopedic surgery * patient is able to understand and provide informed consent to participate in the study. exclusion criteria: patient is prone to coagulopathy. * patient has infection at injection site. * any patient seen immediately before surgery-

Keywords: cancer patients, epidural analgesia, postoperative pain, tunneling
naldebain and video-assisted thoracoscopic surgery

Conditions: Analgesia; Nausea and Vomiting, Postoperative; Itching; Injection Site Reaction; Satisfaction, Patient

Summary: to evaluate the postoperative analgesic effect of combined use of naldebain® and thoracic paravertebral block in thoracoscopic surgery

video-assisted thoracoscopic surgery (vats) can be associated with stronger postoperative pain than is commonly believed. pain control after thoracic surgery is important because increased acute pain has been shown to increase the incidence of chronic pain, and untreated pain may lead to increased morbidity. it is generally accepted to introduce multimodal analgesic strategies based on regional blockade, opioids and non-steroidal anti-inflammatory drugs. paravertebral block (pvb) involves the injection of local anesthetic into a wedge-shaped space lateral to the spinal nerves as they emerge from intervertebral foramina. it produces ipsilateral somatosensory and sympathetic nerve blockade effective for anesthesia as well as for management of pain of unilateral origin from the chest and abdomen. so far, thoracic paravertebral block (tpvb) is the most common technique used for patients undergoing vats. tpvb may be useful after vats because a single injection of local anesthesia may provide effective analgesia for the intense short-duration pain that patients experience. nalbuphine sebacate (naldebain®) is a long-acting prodrug of nalbuphine developed for meeting the unmet medical need of long-acting analgesics. it is a synthetic opioid agonist-antagonist analgesic of the phenanthrene series. it is chemically related to both the widely used opioid antagonist, naloxone, and the potent opioid analgesic, oxymorphone. the currently proposed clinical use of nalbuphine sebacate is a single dose of naldebain® administered intramuscularly approximately 24 h prior to the planned surgery for pain relief. the purpose of this study is to determine the safety and efficacy of tpvb combined with a single dose of intramuscular naldebain® administered preoperatively to patients scheduled to undergo vats.

Eligibility criteria:
inclusion criteria: * 1) subject's age: 20\~65 years old * 2) american society of anesthesiologists (asa) physical status classification: i\~iii * 3) patients who need postoperative pain relief due to thoracoscopic surgery exclusion criteria: * 1. the patient suffers from a communication disorder * 2. the patient has coagulopathy * 3. sick with obvious heart, lung, liver or kidney disease * 4. the patient's body mass index is less than 18.5 or greater than 35 * 5. pregnant patients * 6. patients who took opioids for more than three weeks before surgery * 7. patients with contraindications to local anesthesia * 8. patients with a history of chronic pain * 9. patients with a history of drug allergy to naldebain
erythropoietin effects after traumatic brain injury

Conditions: Traumatic Brain Injury

Summary: to determine if the early administration of erythropoietin to patients sustaining traumatic brain injury will reduce secondary brain injury.

traumatic brain injury occurs with alarming frequency in the united states and is associated with significant morbidity, mortality and economic as well as emotional consequences. since the initial traumatic event produces irreparable primary brain injury, the goal in care of the head injured patient focuses upon the prevention of secondary brain injury. currently, the only clinical strategies available to prevent secondary brain injury relate to the maintenance of adequate cerebral blood flow and regulation of intracranial pressures. now, there is substantial laboratory evidence indicating that secondary neuronal cell death is reduced by the use of recombinant human erythropoietin (epo) in a time-dependent fashion. these data suggest that strategies utilizing epo during the resuscitative phase of head injured patients could improve neurologic outcome. this is a randomized, double-blind, placebo-controlled single-center trial. all blunt trauma patients over 18 years of age with an admission gcs between 9 and 13 and evidence of traumatic brain injury (tbi) on ct will be eligible. after obtaining informed consent, patients will be randomized to receive epo (40,000 units iv) or placebo to be administered within 6 hours of injury. patients will have baseline (day of injury) and daily serum s-100b and nse levels measured until 5 days after injury. demographic and clinical data to be obtained will include age, gender, head ais, iss, admission and icu gcs, daily mean icp and cpp (when icp is monitored), number and nature of icp lowering interventions and daily mean paco2. the primary outcome measures are s-100b and nse levels in patients receiving epo compared to those receiving placebo. secondary outcome measures will include icu los, gcs at icu discharge, 3-month and 6-month glascow outcome score and in-hospital mortality.

Eligibility criteria:
inclusion criteria: * age \> 17, head ct shows intracranial hemorrhage \< 6 hours after injury, gcs\<13 consented exclusion criteria: * nonsurvivable injuries for more then 48 hours, cpr in the field, patients already on erythropoietin

Keywords: traumatic brain injury
impact of vitamin d on acute ischemic stroke prognosis

Conditions: Ischemic Stroke

Summary: this is a registry for all patients admitted to hospital settings with ischemic stroke in mansoura university hospital. the registry will capture patients' data, investigations and vitamin d level on admission. follow-up is taking place using modified rankin scale


Eligibility criteria:
inclusion criteria: * newly diagnosed ischemic stroke not older than 48 hours exclusion criteria: * ischemic stroke due to accidents or any trauma

Keywords: vitamin d ischemic stroke
a study of two approved drugs in patients with osteoarthritis (0966-219)

Conditions: Osteoarthritis

Summary: the purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of osteoarthritis of the knee.

the duration of treatment is 6 weeks.

Eligibility criteria:
inclusion criteria: * osteoarthritis of the knee which requires treatment with medication for pain relief exclusion criteria: * any known allergy to the study drug
focal prostate ablation versus radical prostatectomy

Conditions: Prostate Cancer

Summary: this study aims to compare the treatment results of hifu and radical prostatectomy.

the farp randomized control study will compare focal ablation of prostate using high intensity focused ultrasound (hifu) applied by focalone® or tulsa® device versus radical prostatectomy (rp) in patients with unilateral, intermediate risk prostate cancer.

Eligibility criteria:
inclusion criteria: * positive mri (pirad 3-5) and biopsy proven unilateral prostate cancer classified as isup 1 (with cancer core length \> 5mm) or isup 2-3 (any length) not eligible to active surveillance or watchful waiting * psa ≤ 20 ng/ml * treatment naive patients with localized prostate cancer (stage ≤ t2b) exclusion criteria: * clinical stage t\> 2b * metastatic lymph node on imaging * patients already treated for pca (hormone therapy, ebrt) * patients with contra-indications to mri * patients with active inflammatory bowel disease or previous rectal fistula * history of previous pelvic radiotherapy * history of bladder cancer * history of bladder neck or urethral stricture * urogenital infection in progress * allergy to latex or gadolinium * patients on life support or suffering form unstable neurological diseases

Keywords: prostate cancer hifu and tulsa focal treatment radical prostatectomy
lipo teen (the lifestyle in pregnancy and offspring teenagers

Conditions: Obesity; Life Style, Healthy; Follow-up; Gestational Weight Gain; Body Weight

Summary: the study is a follow-up of a randomized controlled trial (rct) performed in 2007-10 - the "lifestyle in pregnancy" lip study. the lip study included 360 pregnant women with bmi ≥30 kg/m2 from odense university hospital and aarhus university hospital. the women were randomized to intervention with low-calorie diet and physical activity from gestational age 10-14 in pregnancy and until delivery - or to a standard care control group. the objective of the lipo-teen project is to perform a clinical follow-up study of the eligible 301 mothers who completed the trial until delivery with a liveborn child, and their 14 year-old offspring. the overall ambition is to understand whether lifestyle intervention in pregnancy prevents obesity and its complications across generations, with a specific focus on modifiable factors.

lipo teen (the lifestyle in pregnancy and offspring teenagers): identification of modifiable risk factors for childhood obesity - a follow-up of a randomized controlled trial. the objective of the lipo-teen project is to perform a clinical follow-up study of the eligible 301 mothers who completed the trial until delivery with a liveborn child, and their 14 year-old offspring. in the original trial women were randomized 1:1 to intervention or control. the participants (both mother and child in pair) who completed the initial lip study will be invited to a 2-hour examination now 14 years after the intervention during pregnancy to evaluate the effect of the intervention on both mother and child long term.

Eligibility criteria:
inclusion criteria: * mothers in the initial lip study selected at the baseline study in 2007-2010 * teenagers of mothers in the initial lip study exclusion criteria: • none
pelvic binder vs. pelvic c-clamp for bleeding control

Conditions: Pelvic Ring Fracture; Pelvic Bleeding; Polytrauma

Summary: pelvic ring fractures carry a high risk for severe bleeding. expecially bleeding from the posterior ring might result in a fatal course. different types of external emergency stabilization (ees) are available for the posterior pelvic ring, namely the non-invasive pelvic binder or the invasive pelvic c-clamp. which stabilization technique is superior, has not been investigated yet.

severe bleeding is the major cause of death in unstable pelvic ring fractures. therefore, a quick and efficient emergency stabilization and bleeding control is inevitable. the pelvic c-clamp and the pelvic binder are efficient tools for temporary bleeding control, especially for the posterior pelvic ring. however, whether these disadvantages make up for a more efficient bleeding control, still needs to be discussed in the guidelines of the emergency management of pelvic ring fractures. patients with a type-c pelvic ring fracture were identified from the german pelvic registry (gpr). the patients were divided into three groups of 40 patients: 1. group without emergency stabilization, 2. group treated with pelvic binder and 3. group treated with pelvic c-clamp. the patients were matched according to the following parameters: age, gender, initial rr and hb level. the complication rates and mortality rates were compared between the groups, especially regarding bleeding control, as measured by the amount of transfused blood products. furthermore, the subjective efficacy of the treatment was assessed. finally, the time until established bleeding control was compared.

Eligibility criteria:
inclusion criteria: * written informed consent for data acquisition in the german pelvic registry * pelvic ring fracture type c (ao/ota) * iss (abdomen) \>8 exclusion criteria: * acetabular fracture * pelvic ring fracture type a/b (ao/ota) * iss (abdomen) \<9

Keywords: pelvic binder pelvic c-clamp pelvic ring fracture fatal pelvic bleeging emergency stabilization